详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Cancer Institute/ Hospital, Chinese Academy of Medical Sciences, Beijing/CN, [2]Jilin Cancer Hospital, Changchun/CN, [3]Guangdong Lung Cancer Institute, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou/ CN, [4]Beijing Cancer Hospital/institute, Beijing/CN, [5]The 307Th Hospital of Chinese People’s Liberation Army, Beijing/CN, [6]The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou/CN, [7]Hubei Cancer Hospital, Wuhan/CN, [8]Nanjing General Hospital of Nanjing Military Command, Nanjing/CN, [9]Fourth Hospital of Hebei Medical University, Shijiazhuang/CN, [10]Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu/CN, [11]Peking University Third Hospital, Beijing/CN, [12]Chinese People’s Liberation Army General Hospital, Beijing/CN, [13]Fujian Cancer Hospital, Fuzhou/CN, [14]Shanghai Pulmonary Hospital, Tongji University, Shanghai/CN, [15]Cancer Center, Sun Yat-Sen University, Guangzhou/CN, [16]Imed Asia, Astrazeneca, Shanghai/CN

出处：

DOI：

ISSN：

关键词： ctDNA gefitinib EGFR

语种：

被引次数：

WOS：

中科院分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2017]版：

Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 10.34 出版当年[2017版] 7.296 出版当年五年平均 6.595 出版前一年[2016版] 12.46 出版后一年[2018版]

第一作者：

第一作者机构： [1]Cancer Institute/ Hospital, Chinese Academy of Medical Sciences, Beijing/CN,

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal circulating tumor DNA Monitoring in Advanced EGFR-mutant Lung Adenocarcinoma under Gefitinib Treatment. [2]Influence of Autophagy Inhibition on Lung Adenocarcinoma Cell Migration and Invasion Ability, and Efficacy of Gefitinib [3]A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs [4]MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer [5]Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis [6]Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib [7]Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study. [8]Efficacy and safety of first-line gefitinib treatment in metastatic lung adenocarcinoma patients with sensitizing EGFR mutation determined by ddPCR in plasma cell-free DNA (BENEFIT trial) [9]Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases [10]EGFR信号通路与胃癌的抗EGFR治疗